Erasca's ERAS-0015 Posts 44% ORR in Pancreatic Cancer; Phase 3 Moved Up to 1H 2027
ERAS has more than doubled off its 52-week low of $2.75.
Summary
Erasca reported a 44% confirmed ORR for ERAS-0015 in 2L+ KRAS G12X pancreatic cancer and 69% in the G12D/G12V subtypes, with clean safety at the 32 mg dose. The company is accelerating the first-line pancreatic Phase 3 start to the first half of 2027.
Key Events · Product Development and Regulatory · ERAS
-
44% ORR in Pancreatic Cancer
At 32 mg once daily, ERAS-0015 produced a 44% confirmed objective response rate across 25 patients with KRAS G12X pancreatic ductal adenocarcinoma in the 2L+ setting; 84% were treated in the third line or later.
-
69% ORR in G12D/G12V Subtypes
Confirmed ORR reached 69% (N=13) in KRAS G12D or G12V pancreatic cancer, subtypes representing nearly 70% of PDAC patients, split into 63% (N=8) for G12D and 80% (N=5) for G12V.
-
Clean Safety at Active Dose
At 32 mg once daily (N=54), there were no dose-limiting toxicities and no dose discontinuations, with 13.0% dose interruptions, 16.7% dose reductions and 100% median relative dose intensity.
-
Phase 3 Accelerated to 1H 2027
The first-line pancreatic cancer Phase 3 trial start was pulled forward to the first half of 2027, and a potentially registration-enabling 2L+ RAS-mutant NSCLC trial is expected in the same window.
Analysis · ERAS · Life Sciences
Erasca now holds a clinical dataset that supports a best-in-class claim for its pan-RAS molecular glue. In 2L+ KRAS G12X pancreatic cancer, ERAS-0015 at 32 mg once daily delivered a 44% confirmed objective response rate across 25 patients, rising to 69% in the G12D/G12V subtypes that account for nearly 70% of pancreatic cancer. Durability held up: all 11 responders remained on treatment. Safety at the active dose looks manageable, with no dose-limiting toxicities, no discontinuations at 32 mg, and 100% median relative dose intensity. The company is pulling its first-line pancreatic Phase 3 start forward to the first half of 2027 and now plans a potentially registration-enabling 2L+ NSCLC trial in the same window. With $947.8 million in cash as of September 30, this is the kind of data that shifts the pipeline from speculative to near-registrational. Two caveats remain: these are interim results from small cohorts, and the previously disclosed Revolution Medicines patent and trade-secret allegations against ERAS-0015 are still unresolved.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ERAS was trading at $13.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5B. The 52-week trading range was $2.75 to $24.28. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.